Mission Bay Innovation Center

The facility

The Mission Bay Innovation Center: Currently home to more than 20 life science/clean tech companies who occupy over 21,000 square feet of laboratory (chemistry/biology/cell culture) and office space in the FibroGen building, located at 409 Illinois St in Mission Bay. Under the direction of FibroGen, the Innovation Center at 409 Illinois offers small companies the full benefits of sharing in a vibrant life science community. With close proximity to the UCSF Mission Bay campus, companies located here may also contract to use scientific core facilities at UCSF, Gladstone Institute, or UC Berkeley, and are encouraged to attend regular seminars and networking/social events held in the 409 building and on campus. Prospective tenants should contact Catherine Sharpe at casharpe@fibrogen.com.

Tenants

Ablexis

Allopartis

is a biofuel industry company focused on providing technologies for improving the efficiency and decreasing the cost for converting sustainable biomass products into clean-burning fuels.

Carmot Therapeutics, Inc.

China Medical City

Delpor

entrotech life sciences

Evolva Nutrition

Gemmus Pharma, Inc.

GigaGen

Green Pacific Biosciences

is a seed-stage company developing the next-generation eukaryotic algae platform for production of low-cost biofuel. GPB believes that nuclear genetic engineering of algae is the key to overcoming critical problems currently limiting the immense potential of algae-based biofuels. Our foundation for product development is a platform that brings genetic engineering, systems biology, and synthetic biology to generate algae with high levels of oils, oil secretion capabilities, and better growth characteristics.

Kiverdi

upgrades waste carbon into oil using a proprietary bioprocess that is robust against impurities and economical at small scales. Kiverdi’s cutting-edge Carbon EngineeringTM platform uses engineered, gas-consuming microbes that thrive under ambient conditions without the aide of light and can be grown on diverse feedstocks including landfill and agricultural waste—enabling the low-cost conversion of waste carbon into high value products by design. From oil for drop-in fuels to custom oil-based consumer chemicals and biomaterials, Kiverdi makes oil for everyday products.

Medicus Biosciences

is an early-stage, venture-backed start-up company in the San Francisco Bay Area developing break-through polymer technology for biomedical applications. The polymer technology will help save lives and will provide improved quality of life to the patients.

Metafold Therapeutics, Inc.

is developing breakthrough medicines to improve beta-cell function and longevity for the treatment of diabetes mellitus type 2.

Moleculo

OncoSynergy

OptoRobotix

Pathway Therapeutics

Pharmajet

Refactored Materials

manufactures high-value natural materials that cannot be economically extracted from nature. The initial product is dragline spider silk, adapted for large scale production and commercialization. Refactored Spider Silk has potential applications anywhere that stiffness, weight, and failure resistance are valued at a premium, which includes fuel efficient automobiles, high performance aerospace, and military products.

ReqMed Research

SeaChange Pharmaceuticals

uses new computational techniques to identify drugs that may be repurposed, typically for orphan and underserved diseases. SeaChange will run the computational calculations and analysis necessary to expand and test its portfolio of drug ‘off-target’ predictions, which will be validated in vitro by CRO and partnerships.

Siluria Technologies, Inc.

Silver Creek Pharmaceuticals

is developing novel regenerative medicines with an initial focus on treating cardiovascular disease. Using principles of engineering and network biology, Silver Creek is pioneering an entirely new platform of biotherapeutics that can promote resilience and even regeneration of cardiac cells, while minimizing unwanted effects in other tissues.

Solidus Biosciences

provides high-throughput, chip-based toxicology assays. By creating miniaturized array of three-dimensional cell cultures on a chip and incorporating the effects of metabolism into the screen, the Solidus platform delivers toxicity results that are more predictive of human or animal toxicity than standard well-plate screens. The Solidus technology is used by cosmetic companies to replace animal testing in safety assessment and by pharmaceutical companies for early-stage toxicity screening of drug candidates.

Targenics

Tunitas Therapeutics

is poised to develop unique and precisely targeted protein therapeutics that will dramatically change the lives of allergy sufferers. With Tunitas’ proteins, patients receive a treatment regimen in their allergist’s office that will alter the natural course of their disease, providing a therapeutic option with long-lasting benefit.